PLA2G2A is associated with poor survival in patients with esophageal adenocarcinoma [14], glioblastoma [15], rectal cancer [16], and pancreatic ductal adenocarcinoma [17]. This evidence concerns the gene PLA2G2A and pancreatic ductal adenocarcinoma.